

CURRICULUM VITAE

Full Name: Miso Kim

Position Title : Assistant professor

Office address

Division of Hematology/Oncology
Department of Internal Medicine
Seoul National University Hospital

Education

M.D., Seoul National University, Seoul, Korea, 2009.

M.S., College of Medicine, Seoul National University, Seoul, Korea, 2014.

Currently in the doctor's course, College of Medicine, Seoul, National University, Seoul, Korea, 2014-.

Postgraduate Training and Profession

2009.3-2010.2 Internship, Seoul National University Hospital, Seoul, Korea.

2010.3-2014.2 Residency, Internal Medicine, Seoul National University Hospital, Seoul, Korea.

2014.3-2015.2 Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

2015.3-2016.2 Clinical Instructor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

2016.3-present Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

Board Certificate

M.D., Korea, 2009. No. 101186

Board Certification in Internal Medicine, Korea, 2014.

Professional societies or Organizations

Korean Medical Association

Korean Association of Internal Medicine

Korean Society of Medical Oncology

Korean Cancer Association

Updated : Mar 1, 2019

European Society for Medical Oncology

American Society of Clinical Oncology

Previous experience in clinical trials and type of GCP training received

As a PI: 15 studies in the in the oncology field since Jul 1, 2018

As a Sub-I: More than 150 studies in the oncology field since Mar 1, 2015

Last GCP Certification date : May 14, 2018

Publication as main author :

1. Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, et al. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. *The oncologist*. 2018.
2. Kim M, Keam B, Kim TM, Kim HG, Kim JS, Lee SS, et al. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. *Cancer research and treatment : official journal of Korean Cancer Association*. 2017;49(2):416-22.
3. Yoo SH, Kim M, Yun YH, Keam B, Kim YA, Kim YJ, et al. Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey. *Cancer medicine*. 2018;7(5):1784-93. (co-1st author)
4. Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, et al. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. *PLoS one*. 2015;10(7):e0133371.
5. Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, et al. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). *Annals of hematology*. 2015;94(3):437-44.
6. Kim M, Lee DW, Im J, Suh KJ, Keam B, Moon HG, et al. Adenoid cystic carcinoma of the breast: a case series of six patients and literature review. *Cancer research and treatment : official journal of Korean Cancer Association*. 2014;46(1):93-7.
7. Kim M, Chang H, Yang HC, Kim YJ, Lee CT, Lee JH, et al. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. *World journal of surgical oncology*. 2014;12:37.

Updated : Mar 1, 2019